Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
Jim P AbrahamDaniel MageeChiara CremoliniCarlotta AntoniottiDavid D HalbertJoanne XiuPhillip StaffordDonald A BerryMatthew J OberleyAnthony Frank ShieldsJohn L MarshallMohamed E SalemAlfredo FalconeAxel GrotheyMichael J HallAlan P VenookHeinz-Josef LenzAnthony HelmstetterWolfgang Michael KornDavid B SpetzlerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Application of FOLFOXai could lead to improvements of treatment outcomes for patients with mCRC and other cancers because patients predicted to have less benefit from oxaliplatin-containing regimens might benefit from alternative regimens.